Memantine for treatment of moderate to severe Alzheimer's disease

Canadian Coordinating Office for Health Technology Assessment
Record ID 32005000137
English, French
Authors' objectives: The aim of this report is to summarize the use of memantine (trademarked Ebixa, distributed by Lundbeck Canada Inc.)for the treatment of moderate to severe Alzheimer's disease.
Authors' recommendations: Health Canada has issued a Notice of Compliance with conditions for memantine in the treatment of moderate to severe Alzheimer's disease (AD). The evidence of relative benefit and harm from memantine in this population derives from two randomized controlled trials (RCT) of 24 to 28 weeks' duration, in a total of 656 patients, and a post hoc subgroup analysis of 79 patients with severe AD from a third trial of 12 weeks. Memantine alone or in combination with donepezil demonstrates improvements in primary outcome scores of activities of daily living and cognition, but not of global performance. Memantine's rate of diffusion may be rapid, as it is the only drug available for severe AD and it has a potential for use in unapproved indications.
Authors' methods: Overview
Details
Project Status: Completed
URL for project: https://www.ccohta.ca/
Year Published: 2005
URL for published report: n/a
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Canada
MeSH Terms
  • Costs and Cost Analysis
  • Memantine
  • Alzheimer Disease
  • Dopamine Agents
  • Neuroprotective Agents
Contact
Organisation Name: Canadian Coordinating Office for Health Technology Assessment
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name: requests@cadth.ca
Contact Email: requests@cadth.ca
Copyright: Canadian Coordinating Office for Health Technology Assessment (CCOHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.